{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,7]],"date-time":"2026-04-07T16:56:35Z","timestamp":1775580995015,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T00:00:00Z","timestamp":1663200000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The studies described here provide an analysis of the pathogenesis of Blau syndrome and thereby the function of NOD2 as seen through the lens of its dysfunction resulting from Blau-associated NOD2 mutations in its nucleotide-binding domain (NBD). As such, this analysis also sheds light on the role of NOD2 risk polymorphisms in the LRR domain occurring in Crohn\u2019s disease. The main finding was that Blau NOD2 mutations precipitate a loss of canonical NOD2 signaling <jats:italic>via<\/jats:italic> RIPK2 and that this loss has two consequences: first, it results in defective NOD2 ligand (MDP)-mediated NF-\u03baB activation and second, it disrupts NOD2-mediated cross-regulation whereby NOD2 downregulates concomitant innate (TLR) responses. Strong evidence is also presented favoring the view that NOD2-mediated cross-regulation is under mechanistic control by IRF4 and that failure to up-regulate this factor because of faulty NOD2 signaling is the proximal cause of defective cross-regulation and the latter\u2019s effect on Blau syndrome inflammation. Overall, these studies highlight the role of NOD2 as a regulatory factor and thus provide additional insight into its function in inflammatory disease. Mutations in the nucleotide binding domain of the <jats:italic>CARD15<\/jats:italic> (NOD2) gene underlie the granulomatous inflammation characterizing Blau syndrome (BS). In studies probing the mechanism of this inflammation we show here that NOD2 plasmids expressing various Blau mutations in HEK293 cells result in reduced NOD2 activation of RIPK2 and correspondingly reduced NOD2 activation of NF-\u03baB. These <jats:italic>in vitro<\/jats:italic> studies of NOD2 signaling were accompanied by <jats:italic>in vivo<\/jats:italic> studies showing that BS-NOD2 also exhibit defects in cross-regulation of innate responses underlying inflammation. Thus, whereas over-expressed intact NOD2 suppresses TNBS-colitis, over-expressed BS-NOD2 does not; in addition, whereas administration of NOD2 ligand (muramyl dipeptide, MDP) suppresses DSS-colitis in Wild Type (WT) mice it fails to do so in homozygous or heterozygous mice bearing a NOD2 Blau mutation. Similarly, mice bearing a Blau mutation exhibit enhanced anti-collagen antibody-induced arthritis. The basis of such cross-regulatory failure was revealed in studies showing that MDP-stimulated cells bearing BS-NOD2 exhibit a reduced capacity to signal <jats:italic>via<\/jats:italic> RIPK2 as well as a reduced capacity to up-regulate IRF4, a factor shown previously to mediate NOD2 suppression of NF-\u03baB activation. Indeed, TLR-stimulated cells bearing a Blau mutation exhibited enhanced <jats:italic>in vitro<\/jats:italic> cytokine responses that are quieted by lentivirus transduction of IRF4. In addition, enhanced anti-collagen-induced joint inflammation in mice bearing a Blau mutation was accompanied by reduced IRF4 expression in inflamed joint tissue and IRF4 expression was reduced in MDP-stimulated cells from BS patients. Thus, inflammation characterizing Blau syndrome are caused, at least in part, by faulty canonical signaling and reduce IRF4-mediated cross-regulation.<\/jats:p>","DOI":"10.3389\/fimmu.2022.988862","type":"journal-article","created":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T10:20:35Z","timestamp":1663237235000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":34,"title":["Blau syndrome NOD2 mutations result in loss of NOD2 cross-regulatory function"],"prefix":"10.3389","volume":"13","author":[{"given":"Liming","family":"Mao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atika","family":"Dhar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangxun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Fuss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim","family":"Montgomery-Recht","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiqiong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiuyun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kitani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1546-0096-12-33","article-title":"Blau syndrome, the prototypic auto-inflammatory granulomatous disease","volume":"12","author":"Wouters","year":"2014","journal-title":"Pediatr Rheumatol Online J"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217320","article-title":"Clinical characteristics and treatment of 50 cases of blau syndrome in Japan confirmed by genetic analysis of the NOD2 mutation","volume":"79","author":"Matsuda","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0002119","article-title":"The nod-like receptor (NLR) family: a tale of similarities and differences","volume":"3","author":"Proell","year":"2008","journal-title":"PLoS One"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2972","article-title":"Early-onset sarcoidosis and CARD15 mutations with constitutive nuclear factor-kappaB activation: common genetic etiology with blau syndrome","volume":"105","author":"Kanazawa","year":"2005","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0530276100","article-title":"Gene-environment interaction modulated by allelic heterogeneity in inflammatory diseases","volume":"100","author":"Chamaillard","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.emboj.7600175","article-title":"Regulatory regions and critical residues of NOD2 involved in muramyl dipeptide recognition","volume":"23","author":"Tanabe","year":"2004","journal-title":"EMBO J"},{"key":"B7","doi-asserted-by":"publisher","first-page":"11813","DOI":"10.1038\/ncomms11813","article-title":"Crystal structure of NOD2 and its implications in human disease","volume":"7","author":"Maekawa","year":"2016","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1002\/art.24222","article-title":"The NOD2 defect in blau syndrome does not result in excess interleukin-1 activity","volume":"60","author":"Martin","year":"2009","journal-title":"Arthritis Rheumatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-009-1342-4","article-title":"Altered cytokine profiles of mononuclear cells after stimulation in a patient with blau syndrome","volume":"30","author":"Son","year":"2010","journal-title":"Rheumatol Int"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402330","article-title":"Blau syndrome-associated Nod2 mutation alters expression of full-length NOD2 and limits responses to muramyl dipeptide in knock-in mice","volume":"194","author":"Dugan","year":"2015","journal-title":"J Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1126\/science.1104911","article-title":"Nod2-dependent regulation of innate and adaptive immunity in the intestinal tract","volume":"307","author":"Kobayashi","year":"2005","journal-title":"Science"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1172\/JCI62236","article-title":"NOD2-mediated dysbiosis predisposes mice to transmissible colitis and colorectal cancer","volume":"123","author":"Couturier-Maillard","year":"2013","journal-title":"J Clin Invest"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ni1092","article-title":"NOD2 is a negative regulator of toll-like receptor 2-mediated T helper type 1 responses","volume":"5","author":"Watanabe","year":"2004","journal-title":"Nat Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0706097104","article-title":"Chronic stimulation of Nod2 mediates tolerance to bacterial products","volume":"104","author":"Hedl","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2008.42","article-title":"The molecular basis of NOD2 susceptibility mutations in crohn\u2019s disease","author":"Strober","year":"2008","journal-title":"Mucosal Immunol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2014.19","article-title":"NOD2 downregulates colonic inflammation by IRF4-mediated inhibition of K63-linked polyubiquitination of RICK and TRAF6","volume":"7","author":"Watanabe","year":"2014","journal-title":"Mucosal Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0213109","article-title":"RIP2 activity in inflammatory disease and implications for novel therapeutics","volume":"94","author":"Jun","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M112.344283","article-title":"Pathogen sensing by nucleotide-binding oligomerization domain-containing protein 2 (NOD2) is mediated by direct binding to muramyl dipeptide and ATP","volume":"287","author":"Mo","year":"2012","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1042\/BSR20120055","article-title":"Roles of NOD1 (NLRC1) and NOD2 (NLRC2) in innate immunity and inflammatory diseases","volume":"32","author":"Correa","year":"2012","journal-title":"Biosci Rep"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbamcr.2012.03.017","article-title":"Ubiquitination and phosphorylation in the regulation of NOD2 signaling and NOD2-mediated disease","volume":"1823","author":"Tigno-Aranjuez","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-07-2972","article-title":"Muramyl dipeptide activation of nucleotide-binding oligomerization domain 2 protects mice from experimental colitis","volume":"118","author":"Watanabe","year":"2008","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2007.07.025","article-title":"NOD2 transgenic mice exhibit enhanced MDP-mediated down-regulation of TLR2 responses and resistance to colitis induction","volume":"133","author":"Yang","year":"2007","journal-title":"Gastroenterology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041255","article-title":"TRIM27 negatively regulates NOD2 by ubiquitination and proteasomal degradation","volume":"7","author":"Zurek","year":"2012","journal-title":"PLoS One"},{"key":"B24","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/j.jaci.2017.04.013","article-title":"Pluripotent stem cell models of blau syndrome reveal an IFN-gamma-dependent inflammatory response in macrophages","volume":"141","author":"Takada","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.05.084","article-title":"NOD2 suppresses colorectal tumorigenesis via downregulation of the TLR pathways","volume":"19","author":"Udden","year":"2017","journal-title":"Cell Rep"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.10-6263","article-title":"NOD2 deficiency results in increased susceptibility to peptidoglycan-induced uveitis in mice","volume":"52","author":"Rosenzweig","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s10753-014-0030-z","article-title":"Circulating muramyl dipeptide is negatively associayed with interleukin-10 in the frail elderly","volume":"38","author":"Verschoor","year":"2015","journal-title":"Inflamma- tion 2"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1782","article-title":"Activation of innate immune antiviral responses by Nod2","volume":"10","author":"Sabbah","year":"2009","journal-title":"Nat Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.988862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T10:20:41Z","timestamp":1663237241000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.988862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,15]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2022.988862"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.988862","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,15]]},"article-number":"988862"}}